1. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine;Maraskovsky;Vaccine,2012
2. National Institutes of Health. ClinicalTrials.gov, study identifier NCT00959049. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00959049?term=NCT00959049&rank=1 [accessed 28.02.13].
3. Summary Basis for Regulatory Action. CSL Limited Influenza Virus Vaccine/AFLURIA, Timothy Fritz, Ph.D., Review Committee Chair, Food and Drug Administration; December 1, 2011. p. 9–10. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM283336.pdf [accessed 28.02.13].
4. “Pediatric Safety and Utilization Review: Afluria”, Pediatric Advisory Committee Meeting, September 22, 2011; Slide set produced by Michael Nguyen, MD, FDA Center for Biologics Evaluation and Research. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM272852.pdf [accessed 28.02.13].
5. Adverse events associated with 2010 CSL and other inactivated influenza vaccines;Kelly;Med J Aust,2011